Research Analysts Offer Predictions for Myomo Q1 Earnings

Myomo, Inc. (NYSEAMERICAN:MYO) – Equities research analysts at HC Wainwright lifted their Q1 2025 EPS estimates for shares of Myomo in a report issued on Wednesday, March 12th. HC Wainwright analyst S. Lee now forecasts that the company will post earnings per share of ($0.09) for the quarter, up from their prior forecast of ($0.11). HC Wainwright currently has a “Buy” rating and a $9.50 target price on the stock. The consensus estimate for Myomo’s current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Myomo’s Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at ($0.13) EPS and FY2027 earnings at $0.20 EPS.

Several other brokerages have also recently commented on MYO. Alliance Global Partners restated a “buy” rating on shares of Myomo in a research report on Tuesday, March 11th. Ascendiant Capital Markets lifted their price target on shares of Myomo from $9.00 to $11.00 and gave the company a “buy” rating in a report on Monday. Finally, Craig Hallum lifted their price target on shares of Myomo from $9.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday, March 11th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $9.75.

Myomo Stock Down 2.4 %

Shares of Myomo stock opened at $5.31 on Monday. Myomo has a twelve month low of $2.51 and a twelve month high of $7.17. The stock has a market capitalization of $160.63 million, a price-to-earnings ratio of -23.09 and a beta of 1.68.

Insider Transactions at Myomo

In related news, insider Harry Kovelman sold 30,000 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $5.50, for a total transaction of $165,000.00. Following the completion of the transaction, the insider now owns 97,973 shares in the company, valued at approximately $538,851.50. This represents a 23.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Thomas F. Kirk bought 7,400 shares of the business’s stock in a transaction on Thursday, March 13th. The shares were acquired at an average price of $5.00 per share, with a total value of $37,000.00. Following the transaction, the director now directly owns 255,933 shares of the company’s stock, valued at approximately $1,279,665. This trade represents a 2.98 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 4.54% of the company’s stock.

Institutional Investors Weigh In On Myomo

A number of institutional investors and hedge funds have recently modified their holdings of the company. Soleus Capital Management L.P. purchased a new stake in Myomo in the fourth quarter valued at approximately $5,796,000. AIGH Capital Management LLC raised its stake in shares of Myomo by 21.7% during the fourth quarter. AIGH Capital Management LLC now owns 3,381,567 shares of the company’s stock worth $21,777,000 after acquiring an additional 602,719 shares in the last quarter. Portolan Capital Management LLC purchased a new position in shares of Myomo during the fourth quarter worth approximately $2,446,000. Manatuck Hill Partners LLC purchased a new position in shares of Myomo during the fourth quarter worth approximately $1,582,000. Finally, Aristides Capital LLC purchased a new position in shares of Myomo during the fourth quarter worth approximately $1,288,000. 44.99% of the stock is owned by hedge funds and other institutional investors.

Myomo Company Profile

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.